Search
for
Sort by
Research 901–930 of 1000+
- Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
- The new era of JAK inhibitors: Impelling updates in Alopecia Areata Guideline
- Editor’s Picks June 2025
- 26SCS-Loaded SilMA/Col Composite Sponge with Well-Arranged Layers Promotes Angiogenesis-Based Diabetic Wound Repair by Mediating Macrophage Inflammatory Response
- Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity
- T helper type 2 immune response in alopecia areata
- Recommendations on trichological treatments during COVID-19 pandemic
- Update From Dermatology Nurses’ Association Convention 2025
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Activation of mitochondrial aldehyde dehydrogenase 2 promotes hair growth in human hair follicles
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Depletion of <i>Gsdma1/2/3</i> alleviates PMA-induced epidermal hyperplasia by inhibiting the EGFR–Stat3/Akt pathway
- Global, Regional, and National Burden of Alopecia Areata and its Associated Comorbidities, 1990–2021, and Projections to 2050: An Analysis of the Global Burden of Disease Study 2021
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Highlights from the Field of Pediatric Dermatology Research from the 2023 PeDRA Annual Conference
- AAPS and PSRC 2016 Abstract Supplement
- Androgenetic alopecia – Update 2022
- SnapshotDx Quiz: May 2022
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
- Dual effects of human adipose tissue-derived mesenchymal stem cells in human lung adenocarcinoma A549 xenografts and colorectal adenocarcinoma HT-29 xenografts in mice
- From bedside to bench: regulation of host factors in SARS-CoV-2 infection
- Proceedings of the Ninth World Congress for Hair Research (2015)
- Evaluation of the efficacy of topical metformin 10% and 20% versus topical potent steroid in the treatment of patients with alopecia areata
- Real‐world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- Tratamiento de la alopecia areata, un recorrido desde las opciones terapéuticas clásicas hasta los nuevos fármacos aparecidos en los últimos años
- Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata